Article citationsMore>>

Blankenhorn, D.H., Azen, S.P., Kramsch, D.M., Mack, W.J., Cashin-Hemphill, L., Hodis, H.N., DeBoer, L.W., Mahrer, P.R., Masteller, M.J., Vailas, L.I., Alaupovic, P., Hirsch L.J., MARS Research Group (1993) Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (MARS). Annals of Internal Medicine, 119, 969-976. doi:10.7326/0003-4819-119-10-199311150-00002

has been cited by the following article:

• TITLE: Direct anti-atherosclerotic therapy preventing intracellular cholesterol retention

  AUTHORS: Alexander N. Orekhov

  KEYWORDS: Allicor; Anti-Atherosclerotic Therapy; Atherosclerosis; Cell Culture; Drugs; Imaging; Intracellular Cholesterol Retention; Natural Products

  JOURNAL NAME: Health, Vol.5 No.7A, July 16, 2013

  ABSTRACT: The key initiating process in atherogenesis is the subendothelial cholesterol retention, which is both necessary and sufficient to provoke lesion initiation. Retention of cholesterol transported by low density lipoprotien (LDL) in subendothelial cells of arterial wall, is an absolute requirement for lesion development. This allows us to consider intracellular cholesterol retention as a novel target for anti-atherosclerotic therapy. In this case, the target is not the level of blood cholesterol but the level of cholesterol in vascular cells. This review summarizes the results of our basic studies shedding light on the mechanisms of intracellular cholesterol retention. We describe our cellular models to search for anti-atherosclerotic agents and demonstrate the use of these models for the development of anti-atherosclerotic drugs. We use natural products as the basis of anti-atherosclerotic drugs because anti-atherosclerotic therapy should be long-term or even lifelong. Using cellular models and natural products, we have developed an approach to prevent intracellular cholesterol retention in cultured subendothelial aortic cells. We have developed drugs that reduce intracellular cholesterol retention, namely Allicor on the basis of garlic powder, anti-inflammatory drug Inflaminat (calendula, elder, and violet) possessing anti-cytokine activity and phytoestrogen-rich drug Karinat (garlic powder, extract of grape seeds, green tea leaves, hop cones, β-carotene, α-tocopherol, and ascorbic acid). Treatment with Allicor or Inflaminat caused regression of carotid atherosclerosis in asymptomatic men. Karinat prevented the development of new atherosclerotic plaques in postmenopausal women. Thus, the main findings of our basic research have been successfully translated into clinics. As a result, this translation, a novel approach to the development of anti-atherosclerotic therapy, has been established. Our clinical trials have confirmed the suitability of innovative approach and the efficacy of novel drugs developed on the basis our methodology.